keyword
MENU ▼
Read by QxMD icon Read
search

Topical tacrolimus

keyword
https://www.readbyqxmd.com/read/29318025/feline-dry-eye-syndrome-of-presumed-neurogenic-origin-a-case-report
#1
Lionel Sebbag, Patricia A Pesavento, Sebastian E Carrasco, Christopher M Reilly, David J Maggs
Case summary: A 14-year-old female spayed Abyssinian cat, which about 1 year previously underwent thoracic limb amputation, radiotherapy and chemotherapy for an incompletely excised vaccine-related fibrosarcoma, was presented for evaluation of corneal opacity in the left eye (OS). The ocular surface of both eyes (OU) had a lackluster appearance and there was a stromal corneal ulcer OS. Results of corneal aesthesiometry, Schirmer tear test-1 (STT-1) and tear film breakup time revealed corneal hypoesthesia, and quantitative and qualitative tear film deficiency OU...
January 2018: JFMS Open Reports
https://www.readbyqxmd.com/read/29317821/tacrolimus-nanoparticles-based-on-chitosan-combined-with-nicotinamide-enhancing-percutaneous-delivery-and-treatment-efficacy-for-atopic-dermatitis-and-reducing-dose
#2
Kaiyue Yu, Yixuan Wang, Tao Wan, Yuanhao Zhai, Sisi Cao, Wenyi Ruan, Chuanbin Wu, Yuehong Xu
Background: Topical application of tacrolimus (FK506) was effective in the treatment of atopic dermatitis (AD); however, adverse effects frequently occurred with the increase of FK506 dose during long-term treatment. Objective: The objective of this project was to develop a hybrid skin targeting system encapsulating FK506 based on nicotinamide (NIC) and chitosan nanoparticles (CS-NPs), ie, FK506-NIC-CS-NPs, which took advantages of both of NIC and CS-NPs to obtain the synergetic effects of percutaneous delivery and treatment efficacy enhancement along with dose reduction...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29311043/granulomatous-reaction-to-permanent-eyebrow-makeup-successfully-treated-with-topical-steroids-in-combination-with-topical-tacrolimus
#3
Takanori Iwayama, Takeshi Fukumoto, Nobuyuki Horita, Masanobu Sakaguchi, Masahiro Oka, Hiroto Terashi
No abstract text is available yet for this article.
December 1, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29278862/frontal-fibrosing-alopecia-a-retrospective-analysis-of-72-patients-from-a-german-academic-center
#4
Markus V Heppt, Valerie Letulé, Ieva Laniauskaite, Markus Reinholz, Julia K Tietze, Hans Wolff, Thomas Ruzicka, Elke C Sattler
Frontal fibrosing alopecia (FFA) describes the scarring, band-like recession of the frontotemporal hairline. Treatment is difficult, and currently, no evidence-based therapy exists. The purpose of this study is to report clinical features and treatment responses in a large cohort of patients with FFA. The authors analyzed a series of 72 patients with a clinical or histologic diagnosis of FFA. A total of 70 patients were female (97.2%), and 2 were male (2.8%). In females, the first onset of FFA was postmenopausal in 81...
December 26, 2017: Facial Plastic Surgery: FPS
https://www.readbyqxmd.com/read/29260042/conjunctival-squamous-papilloma-refractory-to-interferon-%C3%AE-2b-in-a-patient-on-systemic-immunosuppression-tacrolimus
#5
Preethi S Ganapathy, Thomas Plesec, Arun D Singh
Purpose: To describe a case of diffuse conjunctival papilloma in an immunocompromised individual on tacrolimus that was refractory to treatment with interferon α-2b, but responded to topical mitomycin-c. Observations: A 79-year-old Caucasian female with a history of a liver transplant twenty years ago, who was immunosuppressed with tacrolimus (2 mg daily) presented with a diffuse conjunctival and corneal squamous papilloma. Following treatment with four weekly subconjunctival interferon-α2b injections (3 million units/0...
June 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29248149/morphea-in-childhood-an-update
#6
B Aranegui, J Jiménez-Reyes
Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as localized juvenile scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0...
December 13, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/29234720/radiation-induced-circumscribed-superficial-morphea-after-brachytherapy-for-endometrial-adenocarcinoma
#7
Apoorva Trivedi, Corey M DeWitt, Laura McGevna
Radiation-induced morphea (RIM) is a rare and underrecognized complication of radiation therapy that most commonly occurs in women after treatment for breast cancer. Although not fully understood, RIM is hypothesized to arise from an increase in cytokines that stimulate collagen production and extracellular matrix formation. Most documented cases of RIM occur 1 year after radiation therapy and are localized to areas that were treated for breast cancer. We report on a case of a female patient with stage IB endometrial adenocarcinoma who was treated with 24 Gray of adjuvant brachytherapy...
December 2017: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/29215395/topical-tacrolimus-as-adjuvant-therapy-to-corticosteroids-in-acute-endothelial-graft-rejection-after-penetrating-keratoplasty-a-randomized-controlled-trial
#8
Mohammad Nasser Hashemian, Golshan Latifi, Reza Ghaffari, Hamed Ghassemi, Mehran Zarei Ghanavati, Seyed-Farzad Mohammadi, Mehdi Yasseri, Mohammad Reza Fallah Tafti, Zahra Fallah Tafti
PURPOSE: To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft. METHODS: Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups-group 1: receiving topical tacrolimus 0.05% as adjuvant therapy to corticosteroid treatment and group 2: receiving only corticosteroid treatment. Main outcome measures were rejection reversal, time to rejection reversal, and recurrence of rejection...
December 5, 2017: Cornea
https://www.readbyqxmd.com/read/29205511/mechanistic-insights-on-topical-tacrolimus-for-the-treatment-of-atopic-dermatitis
#9
REVIEW
Takeshi Nakahara, Hiroshi Morimoto, Naofumi Murakami, Masutaka Furue
More than fifteen years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids...
December 4, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29197137/immunohistopathological-characterization-and-the-impact-of-topical-immunomodulatory-therapy-in-oral-chronic-gvhd-a-pilot-study
#10
Ana Carolina F Motta, Qian Zhan, Allison Larson, Mark Lerman, Sook-Bin Woo, Robert J Soiffer, George F Murphy, Nathaniel S Treister
OBJECTIVE: To characterize the immunohistopathologic features of oral chronic graft-versus-host disease (cGVHD), and the impact of topical immunomodulatory therapy on the infiltrating cells. MATERIAL AND METHODS: Paired oral cGVHD biopsies obtained before (n=12) and one month after treatment (n=12) with topical dexamethasone (n=8) or tacrolimus (n=4) were characterized by immunohistochemistry using a panel of CD1a, CD3, CD4, CD8, CD20, CD31, CD62E, CD103, CD163, c-kit and FoxP3...
December 2, 2017: Oral Diseases
https://www.readbyqxmd.com/read/29194735/paradoxic-eczema-in-infants-after-heart-transplantation
#11
Stephanie R Jackson Cullison, Elaine C Siegfried
New-onset psoriasis in patients receiving tumor necrosis factor inhibitors is well recognized in children and adults. We describe three children who underwent cardiac transplantation and developed an analogous form of paradoxic eczema occurring 2-48 months after starting systemic tacrolimus, a drug widely used topically to treat eczema. Anecdotal reports and our experience suggest that tacrolimus taper with alternative systemic antirejection immunosuppressant may lead to skin clearance. Pending additional insight, treatment should include optimizing skin barrier function, minimizing microbial and allergic triggers, and coordinating care to choose the best-tolerated systemic immunosuppressant regimen at the lowest effective dose...
December 1, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/29168213/economic-assessment-of-actual-prescription-of-drugs-for-treatment-of-atopic-dermatitis-differences-between-dermatology-and-pediatrics-in-large-scale-receipt-data
#12
Yoko Komura, Takamichi Kogure, Kazuo Kawahara, Hiroo Yokozeki
Using large-scale receipt data, we analyzed the differences in the prescription of drugs and their costs between dermatology and pediatrics in the treatment of atopic dermatitis (AD) in children. Between August 2010 and July 2011, 50 706 patients were diagnosed as having AD, and the data of 21 075 (15 257 dermatology, 5818 pediatric) patients aged 0-14 years were included in this study. The use of classes I (strongest), II (very strong), and III (strong) topical corticosteroids and tacrolimus was significantly higher in dermatology than in pediatrics (class I, 2...
November 23, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29130957/clinical-disease-patterns-in-a-regional-swiss-cohort-of-34-pyoderma-gangrenosum-patients
#13
Antonios G A Kolios, Alissa Gübeli, Barbara Meier, Julia-Tatjana Maul, Thomas Kündig, Jakob Nilsson, Jürg Hafner, Emmanuella Guenova, Katrin Kerl, Mark Anliker, Werner Kempf, Alexander A Navarini, Lars E French, Antonio Cozzio
BACKGROUND/AIM: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis often associated with an underlying disease, and clinical data or larger studies are rare. METHODS: In this retrospective study, disease characteristics, clinical manifestations, and treatment response were evaluated in a Swiss cohort of PG patients. RESULTS: In participating centers, 34 cases (21 females) of PG were analyzed based on clinical and histological presentation between 2002 and 2012...
November 7, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/29118700/looking-beyond-the-cyclosporine-swish-and-spit-technique-in-a-recalcitrant-case-of-erosive-lichen-planus-involving-the-tongue
#14
Aastha Gupta, Kabir Sardana, Ram Kishan Gautam
Oral lichen planus is a relatively common autoimmune disease affecting the middle-aged population. Although no treatment is necessary for a benign asymptomatic case, in case of erosive lichen planus, topical corticosteroids form the mainstay of treatment. In case of failure, apart from tacrolimus, cyclosporine, using the "swish and spit" technique, is a valid therapeutic intervention. In our case, though, this therapeutic option had to be replaced by the systemic use of cyclosporine with gratifying results.
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29118487/long-term-use-of-0-003-tacrolimus-suspension-for-treatment-of-vernal-keratoconjunctivitis
#15
Abdulrahman Mohammed Al-Amri, Sandra Flavia Fiorentini, Maan A Albarry, Ashjan Yousef Bamahfouz
PURPOSE: To evaluate the safety and efficacy of 0.003% tacrolimus suspension for the treatment of refractory vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: This prospective study included 40 eyes of 20 patients with severe VKC. After discontinuing all other medications, patients were treated with varying doses of 0.003% tacrolimus suspension. All were followed for at least 24 months. Changes in signs and symptoms after treatment were evaluated; adverse events were assessed...
September 2017: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/29066552/fkbp12-dependent-inhibition-of-calcineurin-mediates-immunosuppressive-antifungal-drug-action-in-malassezia
#16
Giuseppe Ianiri, Shelly Applen Clancey, Soo Chan Lee, Joseph Heitman
The genus Malassezia includes yeasts that are commonly found on the skin or hair of animals and humans as commensals and are associated with a number of skin disorders. We have previously developed an Agrobacterium tumefaciens transformation system effective for both targeted gene deletion and insertional mutagenesis in Malassezia furfur and M. sympodialis In the present study, these molecular resources were applied to characterize the immunophilin FKBP12 as the target of tacrolimus (FK506), ascomycin, and pimecrolimus, which are calcineurin inhibitors that are used as alternatives to corticosteroids in the treatment of inflammatory skin disorders such as those associated with Malassezia species...
October 24, 2017: MBio
https://www.readbyqxmd.com/read/28990239/tacrolimus-therapy-for-dermal-arteritis-of-the-nasal-philtrum-refractory-to-surgery-and-anti-inflammatory-therapy-doxycycline-niacinamide-and-topical-fluocinolone-in-a-dog
#17
Frane Banovic, Carmen Jerry, Elizabeth Howerth
BACKGROUND: Dermal arteritis of the nasal philtrum is a rarely reported condition commonly affecting large breed dogs. OBJECTIVE: To describe the effective treatment of nasal philtrum arteritis with topical tacrolimus in one dog. ANIMAL: A 9-year-old, intact male German shorthair pointer dog was presented with well-demarcated deep erythematous ulcers targeting exclusively the skin of the nasal philtrum, accompanied by frequent series of haemorrhage...
October 8, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28972684/the-effects-of-topical-aqueous-sirolimus-on-tear-production-in-normal-dogs-and-dogs-with-refractory-dry-eye
#18
Ronald Spatola, Brad Nadelstein, Andrew Berdoulay, Robert V English
PURPOSE: To evaluate the effect of twice daily aqueous 0.02% sirolimus drops on tear production in normal dogs and dogs with refractory keratoconjunctivitis sicca (KCS). METHODS: Two groups of dogs were studied. Ten normal dogs with no signs of ocular disease were administered topical 0.02% sirolimus ophthalmic solution in right eye, and a vehicle control in the left eye twice daily for 4 weeks. Complete ophthalmic examinations, including Schirmer tear test were performed weekly...
October 3, 2017: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/28966508/plasma-cell-cheilitis-a-clinicopathological-and-immunohistochemical-study-of-13-cases
#19
Jin Yong Lee, Kwang Ho Kim, Ji Eun Hahm, Jae Won Ha, Won Joo Kwon, Chul Woo Kim, Sang Seok Kim
BACKGROUND: Plasma cell cheilitis is an unusual benign plasma cell proliferative disease of an unknown etiology that typically presents on the lip. OBJECTIVE: The aim of this study was to investigate the clinicopathological characteristics of 13 cases of plasma cell cheilitis. METHODS: The present study investigated the clinical manifestations, treatment modalities, and outcome of 13 patients diagnosed with plasma cell cheilitis from 2011 to 2016 at Kangdong Sacred Heart Hospital and Hallym University Sacred Heart Hospital...
October 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28960254/efficacy-and-safety-of-topical-jte-052-a-janus-kinase-inhibitor-in-japanese-adult-patients-with-moderate-to-severe-atopic-dermatitis-a-phase-2-multi-centre-randomised-vehicle-controlled-clinical-study
#20
H Nakagawa, O Nemoto, A Igarashi, T Nagata
BACKGROUND: JTE-052 is a novel Janus kinase inhibitor presently under clinical development for the topical treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of JTE-052 ointment in Japanese adult patients with AD. Methods Patients with moderate-to-severe AD were randomised (2:2:2:2:1:1) to receive JTE-052 ointment at 0.25%, 0.5%, 1% or 3%, the vehicle ointment or 0.1% tacrolimus ointment (reference) twice daily for 4 weeks. The primary efficacy endpoint was the percent change in modified Eczema Area Severity Index (m-EASI) score from the baseline at the end of treatment (EOT)...
September 28, 2017: British Journal of Dermatology
keyword
keyword
71401
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"